期刊
PLOS ONE
卷 10, 期 10, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0140011
关键词
-
资金
- National Institutes of Health [HD076596, DK059820, R01CA112403, 1R01CA181368, 1R01CA183976]
- Cancer Prevention and Research Institute of Texas [R1104, RP100348, RP101251, RP120732-P5]
- Welch Foundation [Q-1798]
- Susan G. Komen Foundation [PG12221410]
- Prostate Cancer Foundation
- Clayton Foundation
- Dunn Foundation
- Center for Drug Discovery and the Metabolomics Core Facility at Baylor College of Medicine
- Dan L. Duncan Cancer Center
- Texas Medical Center Digestive Diseases Center
- John S. Dunn Gulf Coast Consortium
- Shared Equipment Authority instrumentation at Rice University
Triple negative breast cancer (TNBC) has the poorest prognosis of all types of breast cancer and currently lacks efficient targeted therapy. Chemotherapy is the traditional standard-of-care for TNBC, but is frequently accompanied by severe side effects. Despite the fact that high expression of steroid receptor coactivator 3 (SRC-3) is correlated with poor survival in estrogen receptor positive breast cancer patients, its role in TNBC has not been extensively investigated. Here, we show that high expression of SRC-3 correlates with both poor overall survival and post progression survival in TNBC patients, suggesting that SRC-3 can serve as a prognostic marker for TNBC. Furthermore, we demonstrated that bufalin, a SRC-3 small molecule inhibitor, when introduced even at nM concentrations, can significantly reduce TNBC cell viability and motility. However, because bufalin has minimal water solubility, its in vivo application is limited. Therefore, we developed a water soluble prodrug, 3-phospho-bufalin, to facilitate its in vivo administration. In addition, we demonstrated that 3-phospho-bufalin can effectively inhibit tumor growth in an orthotopic TNBC mouse model, suggesting its potential application as a targeted therapy for TNBC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据